Moderna's (MRNA) new COVID-19 shot, mRNA-1283, shows promising results in Phase 3 trials, with comparable efficacy and safety to its approved vaccine. Read more here.
There are still multiple steps required before the shot would become available. Moderna's combo flu and COVID vaccine provided a strong immune response in older adults, with levels comparable to ...
Moderna Inc.’s stock fell 6.4% Wednesday, after the company said that its respiratory syncytial virus, or RSV, shot showed 50 ...
Providing protection against covid in the same shot as the flu could be a sound public health strategy, experts say. (Sholten Singer/AP) Moderna’s combined coronavirus-influenza shot produced a ...
Moderna Inc.’s MRNA, -2.38% experimental combination COVID and flu vaccine triggered better immune responses than stand-alone shots currently on the market, according to clinical trial data the ...
, opens new tab respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday. In their clinical trials, GSK's RSV vaccine ...
Moderna said its combination flu and Covid shot met the goals of a pivotal late-stage trial, bringing the company one step closer to a more convenient jab that could help combat vaccine fatigue.
Moderna said on Thursday its next-generation COVID-19 vaccine candidate met its main goal in a late-stage study by showing ...
Moderna's combo flu and COVID vaccine provided a strong immune response in older adults, with levels comparable to getting the flu and COVID shots separately, according to the company's results ...